Neovasc is a leading brand in the field of cardiovascular care, specializing in the development of minimally invasive therapies for refractory angina and mitral valve regurgitation. With a commitment to clinical rigor, Neovasc collaborates with researchers and clinicians worldwide to advance cardiovascular treatments. Their flagship products, the Reducer™ and Tiara™ systems, are at the forefront of innovation for treating advanced heart disease.

The Reducer is CE-marked for use in the EU and has FDA approval for investigational use in the US. The Tiara system is currently undergoing evaluation in ongoing clinical trials and is not commercially available. Based in Vancouver, BC and Minneapolis, MN, Neovasc is publicly traded on both the NASDAQ and the Toronto Stock Exchange.

They have established themselves as leaders in the industry, driven by a dedicated team of experienced professionals. With a strong focus on patient care and improving lives, Neovasc is revolutionizing the field of cardiovascular care through their groundbreaking therapies, providing hope and better outcomes for patients suffering from these challenging conditions